

OriGene Technologies Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850 UNITED STATES

Phone: +1-888-267-4436 Fax: +1-301-340-8606 techsupport@origene.com OriGene EU

BM6042P

Acris Antibodies GmbH

Schillerstr. 5 32052 Herford GERMANY

Phone: +49-5221-34606-0 Fax: +49-5221-34606-11 info@acris-antibodies.com

Monoclonal Antibody to Ovarian Carcinoma-associated antigen - Supernatant

Catalog No.: BM6042P

Quantity: 1 ml

Background: A central concept in tumor immunology is that malignancies bear tumor associated

antigens, which are not or to a much lesser degree found in normal tissues. These antigens

can be used as distinctive markers in diagnosis and therapy. As a consequence, monoclonal antibodies to such antigens may represent useful tools for histopathology,

immunoscintigraphy and for immunotherapy.

Host / Isotype: Mouse / IgG1
Clone: OVTL-16

Immunogen: Immunized with cyst fluid, obtained from a patient with a poorly differentiated human

ovarian carcinoma.

Format: State: Liquid Culture Supernatant

Preservatives: 0.09% Sodium Azide

Applications: Immunohistochemistry on Frozen Tissues and for staining with avidin-biotinylated

Horseradish peroxidase complex (ABC) as detection reagent.

Other applications not tested. Optimal dilutions are dependent on conditions and should

be determined by the user.

Specificity: OVTL16 recognizes a conformational epitope on ovarian carcinoma membrane antigen OA3

which is present in ovarian carcinomas and in cyst fluids obtained from these carcinomas,

as well as in oviductal carcinomas and some endometrial carcinomas.

Species: Human.

Other species not tested.

Storage: Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.

Avoid repeated freeze-thaw cycles. Shelf life: One year from despatch.

General Readings: 1. Boerman O, Makkink K, Massuger L, Thomas C, Kenemans P, Hanselaar T, et al.

Monoclonal antibodies against ovarian carcinoma-associated antigens, raised by immunization with cyst fluids. Anticancer Res. 1989 May-Jun;9(3):551-8. PubMed PMID:

2764501.

2. Boerman O, Massuger L, Makkink K, Thomas C, Kenemans P, Poels L. Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of antiovarian carcinoma monoclonal antibodies. Anticancer Res. 1990 Sep-Oct;10(5A):1289-95.

PubMed PMID: 2241105.

3. Van Niekerk CC, Ramaekers FC, Hanselaar AG, Aldeweireldt J, Poels LG. Changes in expression of differentiation markers between normal ovarian cells and derived tumors.

TUV NORD
TOWNORD CERT
OFF EN ISO SOL



BM6042P: Monoclonal Antibody to Ovarian Carcinoma-associated antigen - Supernatant

Am J Pathol. 1993 Jan;142(1):157-77. PubMed PMID: 7678716.

- 4. Slobbe R, Poels L, ten Dam G, Boerman O, Nieland L, Leunissen J, et al. Analysis of idiotope structure of ovarian cancer antibodies: recognition of the same epitope by two monoclonal antibodies differing mainly in their heavy chain variable sequences. Clin Exp Immunol. 1994 Oct;98(1):95-103. PubMed PMID: 7523009.
- 5. van Niekerk CC, Vooijs P, Casparie-van Velsen IJ, Poels LG. Differentiation margins of ovarian tumor pathology: first incidences of epithelial ovarian tumors monitored by marker antibodies. Cancer Detect Prev. 1997;21(3):247-57. PubMed PMID: 9167042.

